About
Profile
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
TOVX
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Theriva Biologics GAAP EPS of -$0.34 beats by $0.04
- Theriva Biologics Q2 2023 Earnings Preview
- Theriva shares rally amid FDA orphan drug designation for lead product
- Theriva Biologics GAAP EPS of -$0.30 beats by $0.09
- Theriva Biologics GAAP EPS of -$1.31 misses by $0.01
- Theriva Biologics FY 2022 Earnings Preview
- Theriva Biologics GAAP EPS of -$0.33
- Safety board recommends Synthetic Biologics proceed in cell transplant recipients trial
- Synthetic Biologics VCN-01 shows safety in phase 1 trial in head/neck cancer
- Synthetic Biologics GAAP EPS of -$0.31
- Synthetic Biologics Q2 2022 Earnings Preview
- Synthetic Biologics stock slides on reverse stock split announcement
- Synthetic Biologics GAAP EPS of -$0.03 in-line
- Synthetic Biologics Q1 2022 Earnings Preview
- Synthetic Biologics stock rises as oral drug SYN-020 shows safety in early-stage study
- Synthetic Biologics GAAP EPS of -$0.19 misses by $0.01
- Synthetic Biologics FY 2021 Earnings Preview
- Synthetic Biologics says VCN's therapy for retinoblastoma gets FDA's orphan drug status
- Synthetic Biologics to acquire VCN Biosciences for over $4M in upfront cash
- Synthetic Biologics EPS beats by $0.01